Edwards Lifesciences (EW) Reports Acquisitions of JenaValve and Endotronix
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
TD Cowen Downgrades Edwards Lifesciences (EW) to Hold
July 25, 2024 7:17 AM EDTTD Cowen analyst Joshua Jennings downgraded Edwards Lifesciences (NYSE: EW) from Buy to Hold with a price target of $70.00 (from $100.00).
The analyst comments "We are downgrading EW to Hold as we are now forecasting HSD revenue growth in 2024 and 2025 due to... More
Edwards Lifesciences (EW) PT Lowered to $85 at RBC Capital
July 25, 2024 6:32 AM EDTRBC Capital analyst Shagun Singh lowered the price target on Edwards Lifesciences (NYSE: EW) to $85.00 (from $101.00) while maintaining a Outperform rating.
The analyst comments "EW delivered Q2'24 results missing sales expectations and lowering 2024 operational revenue growth outlook to 8-10%... More
Edwards Lifesciences (EW) PT Lowered to $76 at Evercore ISI
July 25, 2024 4:59 AM EDTEvercore ISI analyst Vijay Kumar lowered the price target on Edwards Lifesciences (NYSE: EW) to $76.00 (from $91.00) while maintaining a In Line rating.
The analyst comments "Thesis Update: This was tough call for EWthe rev miss, low quality EPS (~5c aid from discrete... More
